Skip to main
PODD

Insulet (PODD) Stock Forecast & Price Target

Insulet (PODD) Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 37%
Buy 47%
Hold 11%
Sell 5%
Strong Sell 0%

Bulls say

Insulet is a promising company with a strong financial performance, unique product offerings, and growth potential in new markets. The company's strong cash flow, share repurchase plans, and efforts towards expanding into primary care and the closed-loop system market for Type 2 diabetes are key factors in their success. Ongoing cost reduction and improved gross margins will play a critical role in maintaining their success in the long-term.

Bears say

Insulet is facing increased R&D investments for the development of its Omnipod 6 and closed loop system for T2 diabetic patients, which will not be launched until FY27 and FY28, respectively. This, along with a reduction in the price target by analysts, suggest potential hindered growth and profitability for the company. In addition, the company's current price to sales multiple is significantly higher than the aggregate MedTech space, indicating a potential overvaluation of the stock.

Insulet (PODD) has been analyzed by 19 analysts, with a consensus rating of Buy. 37% of analysts recommend a Strong Buy, 47% recommend Buy, 11% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Insulet and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Insulet (PODD) Forecast

Analysts have given Insulet (PODD) a Buy based on their latest research and market trends.

According to 19 analysts, Insulet (PODD) has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $336.89, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $336.89, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Insulet (PODD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.